“We base our $52 price target on probability-adjusted revenue forecasts for CYAD-01 in r/r AML, and third-line metastatic for metastatic CRC. We use the net present value of our revenue forecast through 2027, apply a 25% POS for 20% POS for 10% POS for 4x price/sales multiple. We include our year-end 2019 estimated fully diluted net cash of $0.97/share (assuming €1.00 = $1.13) to arrive at our price target. Our P/S multiple of 4x is in-line with Celyad’s peers that range between 2-5x.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.0% and a 49.1% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.
Celyad has an analyst consensus of Moderate Buy, with a price target consensus of $52, which is a 146.6% upside from current levels. In a report issued on March 20, William Blair also assigned a Buy rating to the stock.
The company has a one-year high of $37.20 and a one-year low of $15.36. Currently, Celyad has an average volume of 5,186.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
The post Celyad (CYAD) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst.